Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by scroll4factson Apr 05, 2016 8:26am
168 Views
Post# 24731082

RE:Nuvo Nightmare

RE:Nuvo NightmareWhen you say:   "Not even a single offer for P2 ROW",  you seem to forget about Paladin Labs  (Canada) , NovaMedica (Russia and some of the Community of Independent States) and Vianex (Greece).  In my opinion, there must be other very interested parties having serious discussions with them behind the curtains. I mean,  if  I saw P2 capturing an annualized $US221.6 market share in the U.S. in just over a year I'd be interested too. I see this new VP business & development being put in place to make sure they sign the best possible international out-licensing agreements with strong commercial partners. Are-you sure about your nightmare?

https://www.prnewswire.com/news-releases/nuvo-research-announces-successful-pennsaid2-phase-3-trial-for-russia-540749651.html


Bullboard Posts